| 11.1 -0.55 (-4.72%) | 01-21 10:14 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.93 |
1-year : | 17.44 |
| Resists | First : | 12.78 |
Second : | 14.93 |
| Pivot price | 1.09 |
|||
| Supports | First : | 5.07 |
Second : | 0.3 |
| MAs | MA(5) : | 2.6 |
MA(20) : | 0.9 |
| MA(100) : | 0.71 |
MA(250) : | 2.39 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 45.7 |
D(3) : | 37.5 |
| RSI | RSI(14): 98.7 |
|||
| 52-week | High : | 12.78 | Low : | 0.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NVNO ] has closed above the upper band by 43.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 1152.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.81 - 12.86 | 12.86 - 12.91 |
| Low: | 10.64 - 10.69 | 10.69 - 10.74 |
| Close: | 11.57 - 11.65 | 11.65 - 11.73 |
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Tue, 20 Jan 2026
enVVeno Medical Executes One-for-35 Reverse Stock Split - TipRanks
Mon, 19 Jan 2026
enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment - news-leader.com
Sat, 17 Jan 2026
enVVeno Medical Announces Reverse Stock Split - columbiatribune.com
Thu, 15 Jan 2026
EnVVeno Medical announces reverse stock split; shares down 20% - MSN
Thu, 15 Jan 2026
enVVeno Medical announces 1-for-35 reverse stock split - Investing.com
Thu, 15 Jan 2026
What enVVeno's 1-for-35 reverse stock split means for shareholders in 2026 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 20 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 32.9 (%) |
| Shares Short | 60 (K) |
| Shares Short P.Month | 66 (K) |
| EPS | -37.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.2 % |
| Return on Equity (ttm) | -57.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.31 |
| PEG Ratio | 0 |
| Price to Book value | 7.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|